New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
16:52 EDTAGN, SLXP, VRXAllergan all-cash deal would reduce hostile bid chances, says BMO Capital
After Wall Street Journal reported that Allergan (AGN) approached Salix (SLXP) and at least one other company about a takeover, BMO Capital says it believes an all-cash deal or a cash deal and buyback in the $8B-$15B range would "significantly reduce any remaining probability" of a Valeant (VRX) hostile buyout. BMO believes an acquisition in the gastrointestinal space, which is Salix's focus, as well as neurology, oncology or rare diseases could make sense for Allergan. The firm has an Outperform rating on Allergan with a $230 price target.
News For AGN;VRX;SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
19:54 EDTVRXValeant to expand Canadian presence in coming years, Globe and Mail says
Subscribe for More Information
May 20, 2015
06:37 EDTVRXSources: Valeant in talks to buy Amoun Pharmaceutical, Bloomberg reports
Subscribe for More Information
06:32 EDTVRXValeant CEO sees quintupling in Asia sales by 2020, Reuters reports
Subscribe for More Information
May 15, 2015
17:15 EDTVRXPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
17:08 EDTVRXSoros Fund gives quarterly update on stakes
Subscribe for More Information
17:03 EDTVRXPershing Square gives quarterly update on stakes
Subscribe for More Information
10:55 EDTVRXJANA Partners gives quarterly update on stakes
Subscribe for More Information
10:29 EDTAGNAmerican Urological Association to hold an annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use